Intellia Therapeutics Q2 collaboration revenue falls, net loss widens

The current average analyst rating on the shares is hold, with 8 strong buy or buy, 7 hold and 3 sell or strong sell ratings.

The average consensus recommendation for the biotechnology and medical research peer group is buy. Wall Street's median 12-month price target for Intellia Therapeutics is $17.00, about 55% above its Aug. 5 closing price of $10.97.

• Regeneron revenue decline - The company said lower collaboration revenue was primarily due to reduced payments from Regeneron.
• R&D costs down - Intellia attributed lower research and development expenses to reduced external costs for lead programs and lower stock-based compensation, partially offset by higher employee-related expenses.
• Commercial buildout - The company said higher general and administrative expenses were driven by commercial infrastructure buildout, legal expenses and stock-based compensation.